• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: MEDTRONIC SOFAMOR DANEK USA, INC INFUSE BONE GRAFT; FILLER, RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN, COLLAGEN SCAFFOLD WITH MET

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

MEDTRONIC SOFAMOR DANEK USA, INC INFUSE BONE GRAFT; FILLER, RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN, COLLAGEN SCAFFOLD WITH MET Back to Search Results
Catalog Number 7510600
Device Problem Adverse Event Without Identified Device or Use Problem (2993)
Patient Problems Ossification (1428); Inflammation (1932); Neuropathy (1983); Pain (1994); Stenosis (2263); Numbness (2415); Disc Impingement (2655)
Event Type  Injury  
Event Description
It was reported that on (b)(6) 2012, the patient underwent a posterior approach spine fusion surgery on the lumbar region from l1-s1 where rhbmp-2/acs was implanted.Post-operatively, the patient initially had relief, followed by lower back pain.On (b)(6) 2012, a ct scan revealed disc osteophyte and facet arthropathy causing moderate foraminal stenosis on the right at the level of the surgical site.On (b)(6) 2014, a ct scan noted a 9x31x2.5 mm fluid collection dorsal to thecal sac at the implant site.There was also a 6x29mm fluid collection and a broad disc protrusion that contribute to bilateral foraminal narrowing at the levels of surgery.The patient continues to experience consistent lower back pain and numbness, and left lumbar radiculitis that radiates down his lower extremities.The patient is unable to practice and enjoy the activities of daily life that he enjoyed post-operatively.
 
Manufacturer Narrative
(b)(6).(b)(4).Neither the device nor films of applicable imaging studies were returned to the manufacturer for evaluation.Therefore, we are unable to determine the definitive cause of the reported event.Products from multiple manufacturers were implanted during the procedure.Although it is unknown if any of the devices contributed to the reported event, we are filing this mdr for notification purposes.
 
Manufacturer Narrative
(b)(6).
 
Event Description
It was reported that on (b)(6) 2012 the patient underwent 1) gill procedure at l5.2) laminectomy, bilateral at l4 3) foraminotomies, bilateral, at: l3-4, l4-5 and l5-s1.4) internal stabilization from l1 through s1, bilateral, using a pedicle screw and rod system.5) posterior and lateral mass fusion from l1 through s1, bilateral, using autogenous bone plus autologous bone plus bone morphogenic protein.6) preparation of bone graft.7) intraoperative fluoroscopy.Perop notes: the greatest instability was at l5-s1 as anticipated.The spinous processes were resected from l1 through s1.This plus all additional bone removed was debrided of attached soft tissue, mixed with 90ml of cancellous bone chips hydrated in antibiotic containing saline solution, and morcellated in a bone mill for later use of graft.After this gill procedure was carried out.After foraminotomies were carried out at l3-4, l4-5, l5-s1, a bilateral laminectomy was also carried out at l4 including medial facets on each side.Following the completion of the decompressive portion of the procedure, the thecal sac and exiting roots were free of the extrinsic distortion.The remaining bone posteriorly was decorticated with a drill.The facet joint cartilage was resected with a drill and rongeurs.Holes were made through the pedicles bilaterally with a drill at l1, l2, l3, l4, l5 and s1.The holes were tapped and then variable angle head pedicle screws were placed at each site under fluoroscopic control.A single crosslink completed the construct.This provided the rigid stability across the operated levels and returned to the spine to normal alignment.The bone graft prepared, as previously described, was placed bilaterally over the decorticated bone from l1 through s1 and packed within the remaining facet joint spaces.Two large rhbmp-2/acs packages were reconstituted according to the supplier's instructions and allowed to assimilate for more than 45mins.The rhbmp-2/acs was carefully placed over the bone graft bilaterally from l1 through s1, taking care to make sure none entered the spinal canal at any time.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
INFUSE BONE GRAFT
Type of Device
FILLER, RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN, COLLAGEN SCAFFOLD WITH MET
Manufacturer (Section D)
MEDTRONIC SOFAMOR DANEK USA, INC
4340 swinea rd
memphis TN 38118
Manufacturer (Section G)
MEDTRONIC SOFAMOR DANEK
1800 pyramid place
memphis TN 38132
Manufacturer Contact
greg anglin
1800 pyramid place
memphis, TN 38132
9013963133
MDR Report Key4513196
MDR Text Key5440978
Report Number1030489-2015-00290
Device Sequence Number1
Product Code NEK
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P000058
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type Consumer,consumer
Reporter Occupation Attorney
Type of Report Initial,Followup
Report Date 01/15/2015
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received02/12/2015
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Expiration Date12/31/2014
Device Catalogue Number7510600
Device Lot NumberM111108AAF
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? No
Date Manufacturer Received01/15/2015
Was Device Evaluated by Manufacturer? No
Date Device Manufactured03/27/2012
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Other;
-
-